London English news | London, Latest News & Live Updates in English | English News (Latest English News) at Lokmattimes.com

London, Sep 15 The two-dose vaccine against Ebola virus developed by US drug maker Johnson and Johnson is safe, well tolerated and produces a strong immune response in people over the age of one, according to two new papers published in The Lancet Infectious Diseases.The study provides important further evidence for the potential of the regimen using the Ad26.ZEBOV and MVA-BN-Filo vaccines to be used as a protective measure against Ebola virus disease for both children and adults.The researchers from London School of Hygiene and Tropical Medicine (LSHTM) and Sierra Leone's College of Medicine and Allied Health Sciences (COMAHS) found that the vaccine regimen was well tolerated and induced antibody responses to Zaire ebolavirus 21 days after the second dose in 98 per cent of participants, with the immune responses persisting in adults for at least two years.During the 2014-16 outbreak of Ebola in West Africa, 28,652 cases and 11,325 deaths from Ebola were reported. Approximately 20 per cent of cases were in children under 15 years, and children younger than five years are at a higher risk of death than adults."This study represents important progress in the development of an Ebola virus disease vaccine regimen for children, and contributes to the public health preparedness and response for Ebola outbreaks," said Dr Muhammed Afolabi, Assistant Professor at LSHTM."The results show that this vaccine regimen has the potential to save many young lives," he added.For the clinical trial, divided into two stages, the team recruited participants from September 2015 to July 2018. In stage one, which aimed to gain initial information about the vaccine regimen's safety and immunogenicity, 43 adults aged 18 years or older received the Ad26.ZEBOV vaccine followed by the MVA-BN-Filo vaccine after 56 days.In stage two, 400 adults and 576 children and adolescents (192 in each of the three age cohorts of 1-3, 4-11 and 12-17 years of age) were vaccinated with either the Ebola vaccine regimen (Ad26.ZEBOV followed by MVA-BN-Filo) or a single dose of a meningococcal quadrivalent conjugate vaccine followed by placebo on day 57.Adults participating in stage one of the study were offered a booster dose of A26.ZEBOV two years after the first dose which induced a strong immune response within seven days.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

LondonFOLLOW

London, Latest News

London, Sep 16 British actor Stephen Fry will deliver the 2021 MCC Cowdrey Lecture at the Lord's Cricket ... ...

London, Sep 16 Good amount of Vitamin D in the body before Covid-19 infection can prevent severe disease ... ...

London, Sep 16 The 'Vengabus' is back with 'Boom' as the '90s party anthem band Vengaboys takes us ... ...

London, Sep 16 UK Prime Minister Boris Johnson has reshuffled his cabinet with an aim to put in ... ...

London, Sep 16 Another 30,597 people in Britain have tested positive for Covid-19, bringing the total number of ... ...

Sumit Sangwan and Neeraj Swami were among the boxers to register victories on the opening day of the 5th Elite Men's National Boxing Championships at the Inspire Institute of Sports in Bellary on Wednesday. ...

Aurangabad, Sept 15: Fighting all odds coming in his way, a city youth Hardeep Singh Siledar, who hails from ... ...

London, Sep 15 The two-dose vaccine against Ebola virus developed by US drug maker Johnson and Johnson is ... ...